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Abstract HLA class I loss is a signiﬁcant mechanism of
immune evasion by cervical carcinoma, interfering with the
development of immunotherapies and cancer vaccines. We
report the systematic investigation of HLA class I and
antigen processing machinery component expression and
association with clinical outcome. A tissue microarray
containing carcinoma lesions from 109 cervical carcinoma
patients was stained for HLA class I heavy chains, b2-mi-
croglobulin, LMP2, LMP7, LMP10, TAP1, TAP2, ERAP1,
tapasin, calreticulin, calnexin and ERp57. A novel staining
evaluation method was used to ensure optimal accuracy and
reliability of expression data, which were correlated with
known clinicopathological parameters. Partial HLA class I
loss was signiﬁcantly associated with decreased 5-years
overall survival (61% vs. 83% for normal expression;
P < 0.05) and was associated with decreased 5-years dis-
ease-free survival (DFS) (65% vs. 82% for normal expres-
sion; P = 0.05). All APM components except LMP10,
calnexin and calreticulin were down-regulated in a sub-
stantial number of cases and, except ERAP1, correlated
signiﬁcantly with HLA class I down-regulation. LMP7,
TAP1 and ERAP1 loss was signiﬁcantly associated with
decreased overall and (except LMP7) DFS (P < 0.05
and 0.005, respectively). ERAP1 down-regulation was an
independent predictor for worse overall and DFS in multi-
variate analysis (HR 3.08; P < 0.05 and HR 2.84; P < 0.05,
respectively). HLA class I and APM component down-
regulation occur frequently in cervical carcinoma, while
peptide repertoire alterations due to ERAP1 loss are a major
contributing factor to tumour progression and mortality.
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Introduction
Tumour cells utilize several mechanisms to escape
immune-mediated recognition and destruction [1]. Loss of
surface-expressed human leukocyte antigen (HLA) class I
molecules is particularly important, as this enables tumour
cells to evade recognition and lysis by cytotoxic T-lym-
phocytes [2–5]. These molecules consist of a glycoprotein
heavy chain (encoded by genes within the HLA regions of
chromosome 6p) and a b2-microglobulin (b2-m) light chain
(encoded on chromosome 15q) [6, 7].
Defects in HLA class I expression are caused by
multiple mechanisms, including loss of heterozygosity at
chromosome 6p; b2-m or HLA class I mutations; and
defective expression and/or function of components of the
antigen processing machinery (APM) [8–10]. The APM is
the combination of cellular processes responsible for the
presentation of endogenous peptides by HLA class I
molecules. These peptides are generated by specialized
immunoproteasomes (composed of LMP2, LMP7 and
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the endoplasmic reticulum by TAP (transporter associated
with antigen presentation) which is composed of TAP1 and
TAP2 subunits. Transported peptides undergo length-
speciﬁc trimming by ERAP1 (endoplasmic reticulum
aminopeptidase associated with antigen presentation 1) and
are loaded onto empty HLA class I molecules (with
involvement of tapasin and the chaperone molecules
calnexin, calreticulin and ERp57) [11–14].
Although various in vitro studies have demonstrated
partial or total APM component loss in human malignan-
cies, the extent to which this occurs in vivo is largely
unknown. Two recent reports describe down-regulation of
several APM components in head and neck squamous cell
carcinoma and astrocytoma, and demonstrate an associa-
tion of these defects with prognosis [15, 16]. As HLA class
I-restricted processing and presentation of endogenous
peptides is crucial to the generation of a virus-speciﬁc
cytotoxic T-lymphocyte-mediated reaction, APM defects
are assumed to contribute signiﬁcantly to virus-mediated
carcinogenesis. Several studies have conﬁrmed interfer-
ence in various APM processes by viral peptides [17].
However, the extent to which defective expression of APM
components contributes to HPV-induced cervical carcino-
genesis remains to be established. One study has assessed
the expression of various APM components, although only
at the mRNA level [18]. Other studies of APM component
expression in cervical carcinoma were largely limited to
TAP1 and TAP2 and encompassed relatively small sample
sizes. Moreover, the expression data yielded by these
studies are conﬂicting, with TAP1 loss being reported in
0–50% of cases [18–20]. Though TAP1 and HLA class I
down-regulation has occasionally been shown to be asso-
ciated with progressive malignant transformation [21–24],
a comprehensive study of the association of APM defects
with prognostic parameters has yet to be performed.
Since information regarding defective APM component
expression in cervical cancer can contribute to the devel-
opment of T cell-based immunotherapies, we have inves-
tigated the expression of all known APM components in a
large number of cervical cancer specimens using a tissue
microarray (TMA)-based approach [25, 26]. Additionally,
we demonstrate for the ﬁrst time a negative association of
APM defects with prognosis and other clinicopathological
variables.
Materials and methods
Clinical characteristics and tissue samples
From 109 patients with cervical carcinoma who underwent
radical hysterectomy with bilateral pelvic lymphadenectomy
(by the same surgical team) between 1985 and 1999,
formalin-ﬁxed, parafﬁn-embedded tissue blocks were
retrieved from the archives of the Department of Pathol-
ogy, Leiden University Medical Centre, The Netherlands.
Twenty-six adenocarcinomas and 83 squamous carcinomas
were obtained. These cases were not consecutive, but
chosen on the basis of availability of sufﬁcient material.
The use of clinical material was approved by the institu-
tional review board according to the guidelines of the
Dutch Federation of Medical Research Associations.
All patients were inhabitants of The Netherlands and
had not received pre-operative radiotherapy or chemo-
therapy. Mean age was 48.5 years, the youngest patient
being 24 years and the oldest 87 years at the time of sur-
gery. Follow-up of these patients until 2005 provided
information concerning recurrence rate and performance
state.
Tissue microarray construction
The archival slides for all the cases were reviewed; a
slide containing representative tumour was selected,
and an area of tumour was encircled on the slide. The
corresponding tissue blocks were recovered from the
archives and the selected area on the slide was circled
on the block for tissue microarray construction. Using a
manual tissue microarrayer (Beecher Instruments, Silver
Spring, MD, USA), the area of interest in the donor
block was cored with a 0.6-mm diameter needle and
transferred to a recipient parafﬁn block. The microarray
was constructed with a threefold redundancy (three spots
for each patient) to increase accuracy. The ﬁnalized
arrays were then cut into 3 lm-thick sections and
mounted on glass slides using an adhesive tape-transfer
system (Instrumedics Inc., Hackensack, NJ, USA) with
ultraviolet cross-linking.
Antibodies
The mouse monoclonal antibody (mAb) HCA2 which
recognizes a determinant expressed on b2-m-free HLA-A
(excluding HLA-A24), HLA-B7301 and HLA-G heavy
chains [27, 28], the mAb HC10 which recognizes a
determinant on all b2-m-free HLA-B and HLA-C heavy
chains and on b2-m-free HLA-A10, -A28, -A29, -A30,
-A31, -A32 and -A33 heavy chains [27, 29], the
LMP2-speciﬁc mAb SY1 [30], the LMP7-speciﬁc mAb
HB-2 [30], the LMP10-speciﬁc mAb TO-7 [30], the
TAP1-speciﬁc mAb NOB-1 [31], the TAP2-speciﬁc mAb
NOB-2 [31], the calnexin-speciﬁc mAb TO-5 [32], the
calreticulin-speciﬁc mAb TO-11 [32], the Erp57-speciﬁc
mAb TO-2 [32] and the tapasin-speciﬁc mAb TO-3 [32]
were developed and characterized as described.
198 Cancer Immunol Immunother (2008) 57:197–206
123The rabbit polyclonal anti-b2-m-antibody A-139 was
purchased from DAKO, Copenhagen, Denmark. The rabbit
polyclonal anti-ERAP1 antibody has been described pre-
viously and was kindly provided by Dr. M. Tsujimoto,
RIKEN, Wako, Saitama, Japan [33–35].
Immunohistochemical staining
The slides were dried for 16 h at 56 C before being
dewaxed with standard xylene and rehydrated through
graded alcohols into water. Standard immunohistochemical
staining was performed as described previously [36].
Stromal cells, including inﬁltrating leukocytes, were used
as internal positive controls. Negative control sections of
each specimen were processed with omission of the pri-
mary antibodies.
Evaluation of TMA immunostaining
Two researchers (A.M. and E.J.) evaluated all patient
cores, and scores were averaged to produce a single eval-
uation with the scorers being blind to the source of the
samples. When slides were scored differently, which
occurred rarely (<5%), a consensus was reached by
simultaneous evaluation. Staining was scored semi-quan-
titatively by the quality control system proposed by Ruiter
et al. [37]. The intensity and percentage of positive cells in
the tumour and the stromal cells surrounding the tumour
were determined. The intensity of staining was scored as
0, 1, 2, or 3 indicating absent, weak, clear, or strong
expression, respectively. The percentage of positive cells
was scored as 0 for 0%; 1 for 1–5%; 2 for 5–25%; 3 for
25–50%; 4 for 50–75% and 5 for 75–100%. The sum of
both scores was used to identify three categories of
expression: normal expression (total score 7–8), partial loss
(3–6) and total loss (0–2). Immunohistochemical staining
demonstrated strong positive expression of all examined
markers in stromal tissue and tumour-inﬁltrating inﬂam-
matory cells, thereby providing an internal positive control.
Statistical analysis
The Chi-square test or, where appropriate, Fisher’s exact
test was used for evaluation of associations between
expression and clinicopathological parameters. All statis-
tical analyses were performed with the SPSS Version 12
software package. Five-year survival rates were calculated
and survival rates were compared according to the Kaplan–
Meier method using the log rank test, while multivariate
analysis of survival was performed according to Cox pro-
portional hazard models. Overall survival (OS) was deﬁned
as survival till death due to cervical carcinoma (the two
patients that dyed from other causes were excluded),
i.e. disease-speciﬁc survival, while disease-free survival
(DFS) was deﬁned as time to disease recurrence, metasta-
sis, or disease-speciﬁc death. All tests were two-sided and
the signiﬁcance level was set to 5%.
Results
Clinical features
Of the total group of 109 patients, 52 were diagnosed as
FIGO stage IB1, 30 as IB2, 21 as FIGO IIa and 2 as FIGO
IIb. For four patients no FIGO staging was available. Fifty-
ﬁve patients (50%) received post-operative radiotherapy
due to narrow tumour-free margins of excision, lymph
node metastases, vaso-invasive growth, parametrial inﬁl-
tration, depth of inﬁltration exceeding 15 mm and/or
tumour size exceeding 4 cm. Twenty-seven patients had
lymph node metastases. Fifty-one patients (58%) were
HPV16-positive, 21 (24%) were HPV18-positive, while the
remaining patients were positive for HPV31, HPV33,
HPV45, HPV52 or HPV68. At the end of follow-up, 80
patients were alive, 2 suffered from recurrent disease, 3 had
a metastasis, 22 had died of the disease and 2 had died of
causes unrelated to the primary disease. The median
follow-up time was 45 months.
HLA class I and APM component expression
Representative staining patterns for the HLA class I heavy
chains and various APM components are shown in Figs. 1
and 2. Expression of the HLA class I heavy chains and b2-m
is summarized in Table 1. Of the 109 cases, eight exhibited
total b2-m loss; correspondingly, these cases were also
negative for HLA heavy chain cell surface expression. As
HLA class I expression, and therefore tumour immuno-
genicity, is not affected by the APM in a b2-m-negative
background these eight cases were excluded from further
analysis of APM effects. Furthermore, as HLA class I
expression is regulated by the APM in a b2-m-independent
manner, the overall HLA class I expression score was based
on expression of the heavy chains. If either or all the heavy
chains were expressed normally, overall HLA class I
expression was considered to be normal. Total loss of all
heavy chains was counted as total HLA class I loss, and all
other cases were counted as partial loss.
As shown in Table 2, expression of all APM compo-
nents except LMP10, calnexin, and calreticulin was lost in
some of the cases. This down-regulation was signiﬁcantly
associated with HLA class I down-regulation for all com-
ponents, except ERAP1. Moreover, defects in overall TAP
expression (deﬁned as partial or total loss of either or both
of the TAP subunits) were signiﬁcantly associated with
Cancer Immunol Immunother (2008) 57:197–206 199
123HLA class I down-regulation (P <0 . 0 0 1 ) .D o w n - r e g u l a t i o n
of any APM component was signiﬁcantly associated with
HLA class I down-regulation (P < 0.001).
Association with histopathological parameters
Depth of invasion exceeding 15 mm and vaso-invasive
growth are unfavourable prognostic indicators. Of the cases
examined, 51 (45%) demonstrated depth of invasion
greater than 15 mm and 38 (33%) demonstrated vaso-
invasive growth. Total loss of overall HLA class I
expression and of any APM component was found to be
signiﬁcantly associated with depth of invasion exceeding
15 mm (P = 0.034 and 0.045, respectively), while no sig-
niﬁcant association was found for defective expression of
any marker and vaso-invasion.
None of the markers was found to be signiﬁcantly
associated with FIGO stage, corresponding to the lack of a
signiﬁcant association with histopathological parameters.
No association of any of the markers with speciﬁc HPV
status of the patients was detected. Interestingly, partial
LMP2 and/or LMP7 loss was signiﬁcantly associated
with an absence of detectable lymph node metastases
(P = 0.023 and 0.021, respectively).
Fig. 1 Immunohistochemical
analysis. Staining patterns of
a–c HLA-A, d–f HLA-B/-C,
g–i LMP7 and j–l TAP1
showing a, d, g, j normal
expression, b, e, h, k partial loss
of expression and c, f, i, l total
loss of expression
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As shown in Table 3 and Figs. 3 and 4, partial loss of
overall HLA class I expression was signiﬁcantly associated
with decreased OS, and exhibited a trend towards a sig-
niﬁcant association with DFS, whereas total loss was not
signiﬁcantly associated with survival. Moreover, partial
HLA-A loss (evaluated by HCA2 reactivity) was signiﬁ-
cantly associated with decreased OS and DFS, whereas
total loss was not signiﬁcantly associated with survival.
Partial, but not total HLA-B/-C loss (assessed by HC10
reactivity) showed a trend towards signiﬁcant association
with decreased survival.
Decreased OS and DFS was signiﬁcantly associated
with total TAP1 loss, but not with normal expression and
partial loss. A similar pattern was observed for partial
LMP7 loss, though this was not signiﬁcantly associated
with DFS. ERAP1 loss was signiﬁcantly associated with
Fig. 2 Immunohistochemical
staining patterns of ERAP1.
a Normal expression. b Partial
loss of expression
Table 1 Expression of HLA class I heavy chains, b2-microglobulin and overall HLA class I
HLA-A HLA-B/-C b2-microglobulin HLA class I
Total
loss
Partial
loss
Normal
expression
Total
loss
Partial
loss
Normal
expression
Total
loss
Partial
loss
Normal
expression
Total
loss
Partial
loss
Normal
expression
Overall (n = 109) 36 (33) 22 (20) 51 (47) 24 (22) 29 (27) 56 (51) 8 (7) 28 (26) 73 (67) 21 (19) 24 (22) 63 (59)
Tumour type
AC (n = 26) 6 (23) 5 (19) 15 (58) 4 (15) 8 (31) 14 (54) 1 (4) 7 (27) 18 (69) 4 (15) 5 (19) 17 (66)
SCC (n = 83) 30 (36) 17 (21) 36 (43) 20 (24) 21 (25) 42 (51) 7 (8) 21 (25) 55 (67) 17 (21) 19 (23) 46 (56)
Data shown as n (%)
Table 2 Overall and histological type-speciﬁc expression of APM components
Overall (n = 101) AC (n = 25) SCC (n = 76)
Total
loss
Partial
loss
Normal
expression
P Total
loss
Partial
loss
Normal
expression
P Total
loss
Partial
loss
Normal
expression
P
LMP2 14 (14) 30 (30) 57 (56) 0.014 5 (20) 11 (44) 9 (36) 0.772 9 (12) 19 (25) 48 (63) 0.001
LMP7 3 (3) 16 (16) 82 (81) <0.001 2 (8) 9 (36) 14 (56) 0.100 1 (1) 7 (9) 68 (90) <0.001
LMP10 0 0 101 (100)
TAP1 4 (4) 19 (19) 78 (77) <0.001 0 (0) 4 (16) 21 (84) 0.230 4 (5) 15 (20) 57 (75) 0.001
TAP2 11 (11) 26 (26) 64 (63) <0.001 4 (16) 6 (24) 15 (60) 0.005 7 (9) 20 (26) 49 (65) <0.001
ERAP1 0 14 (15) 80 (85) 0.314 0 (0) 2 (9) 20 (91) 0.582 0 12 (16) 60 (84) 0.307
Tapasin 1 (1) 24 (24) 76 (75) <0.001 0 (0) 10 (40) 15 (60) 0.284 1 (1) 14 (18) 61 (81) <0.001
Calnexin 0 0 101 (100)
ERp57 12 (12) 40 (40) 49 (48) 0.017 1 (4) 6 (24) 18 (72) 0.615 11 (15) 34 (45) 31 (40) 0.002
Calreticulin 0 0 101 (100)
Data shown as n (%). P values are shown for association with overall HLA class I down-regulation
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expression.
Multivariate analysis
As expected, well known prognostic parameters such as
depth of inﬁltration exceeding 15 mm, presence of vaso-
invasive growth, and presence of lymph node metastases
were signiﬁcantly associated with a shorter survival, while
FIGO-stages of IB2 or more showed a signiﬁcant associ-
ation with shorter DFS (Table 4). HPV type was not
signiﬁcantly associated with survival (data not shown).
Subsequently, multivariate analysis was performed on
overall HLA class I, TAP1, LMP7 (for OS only) and
ERAP1 expression, combined with the aforementioned
prognostic factors. ERAP1 down-regulation was demon-
strated to be an independent prognostic parameter for
shorter OS (hazard ratio (HR) 3.08; 95% CI 1.07–8.90;
P = 0.037) and shorter DFS (HR 2.84; 95% CI 1.01–8.03;
P = 0.049), as was presence of lymph node metastases (HR
7.02; 95% CI 2.55–19.32; P < 0.001 for OS and HR 6.64;
95% CI 2.53–17.44; P < 0.001 for DFS). Total TAP1 loss
was also an independent predictor for shorter DFS (HR
6.72; 95% CI 1.29–35.06; P = 0.024).
Discussion
In the present study we have investigated HLA class I and
APM component expression in cervical carcinoma patients
and have evaluated the relationship of these factors with
survival and other clinicopathological parameters.
Our results show that HLA class I down-regulation
occurs frequently (~40% of cases) in cervical carcinoma,
corresponding to previous reports [19, 21]. Synchronous
partial or total loss of various APM components was found
in a substantial number of cases and was demonstrated to
be signiﬁcantly associated with HLA class I down-regu-
lation. We observed partial HLA class I loss to be signif-
icantly associated with decreased OS. Of the APM
components, TAP1, LMP7 and ERAP1 down-regulation
exhibited signiﬁcant associations with decreased survival.
ERAP1 down-regulation was shown to be an independent,
signiﬁcant predictor of shorter survival.
Though defective APM component expression is
hypothesized to be an important mechanism of HLA class I
down-regulation and therefore immune evasion by tumour
cells, information regarding APM down-regulation in car-
cinomas is limited. This is partly due to the scarcity of
reliable antibodies for most APM components other than
the TAP subunits. Furthermore, most previous studies of
APM expression in cervical cancer were limited by small
sample sizes. Lastly, the use of various scoring methods for
evaluation of immunohistochemical staining has rendered
proper interpretation of ﬁndings difﬁcult, leading to
conﬂicting data, e.g. regarding the frequency of TAP1 loss
[9, 18–20].
In this study, a panel of recently reported monoclonal
antibodies was used to investigate expression of all known
APM components in a large set of cervical carcinoma
lesions using a TMA-based approach [30–33]. Staining was
evaluated according to a previously reported quality con-
trol system [37], which is more stringent in deﬁning total
and partial expression loss than other evaluation methods,
which consider £25% positive cells as total loss. The
system used here deﬁnes total loss as complete or near-
complete negativity and is therefore more reliable. More-
over, by excluding b2-m-negative cases from the analysis,
all outcome parameters can be reliably correlated to
expression levels of the various APM components, as any
inﬂuence of defective APM expression will only be
detectable in a b2-m-positive setting.
As an APM component, ERAP1 has been shown to be
an important determinant of the repertoire of HLA class
I-presented peptides [14, 34, 38–41]. However, to date no
systematic investigation of its potential role in HLA class I
down-regulation in tumours has been performed. To our
knowledge, this is the ﬁrst description of ERAP1 down-
regulation in a human carcinoma. Additionally, we have
identiﬁed ERAP1 loss as an independent predictor of
Table 3 HLA class I and APM component expression and 5-years survival rates
Overall survival Disease-free survival
Normal expression Partial loss Total loss Normal expression Partial loss Total loss
HLA-A 42 (83) 12 (55) 29 (81) 42 (83) 13 (60) 28 (77)
HLA-B/-C 45 (81) 19 (64) 18 (75) 46 (82) 19 (67) 18 (73)
HLA class I 52 (83) 15 (61) 16 (77) 52 (82) 16 (65) 15 (75)
LMP7 24 (74) 17 (87) 1 (33) 62 (76) 13 (80) 2 (50)
TAP1 61 (78) 8 (70) 1 (33) 63 (81) 13 (67) 1 (25)
ERAP1 66 (82) 5 (38) – 65 (81) 7 (50) –
Data shown as n (%)
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down-regulation. A possible explanation for this observa-
tion is the role of ERAP1 in shaping the antigen repertoire:
ERAP1 down-regulation may lead to the preferential
loading and presentation of non-tumour-associated pep-
tides, thereby yielding a less immunogenic phenotype and
facilitating tumour growth and progression. This hypothe-
sis is supported by previous reports on the disrupted nature
of presented peptide repertoire in ERAP1-deﬁcient mice
[41, 42]. Also, the effect of down-regulation of several
APM components on the presentation of speciﬁc HPV 16
E6-derived epitopes has been ﬁrmly established [43–45].
Although we found that total TAP1 loss was an inde-
pendent predictor for shorter DFS, this ﬁnding should be
interpreted with caution as only four patients exhibited this
loss. The decreased signiﬁcance of ERAP1 as an inde-
pendent predictor for shorter DFS can be explained by the
interdependency of ERAP1-mediated peptide trimming and
TAP-mediated peptide transport.
An interesting ﬁnding in this study is the observed
association of LMP2 and LMP7 down-regulation with an
absence of lymph node metastasis; this ﬁnding is seem-
ingly corroborated by reports that certain immunogenic
peptides in melanoma and renal-cell carcinoma are not
generated by immunoproteasomes and that presentation
of these peptides is reduced upon up-regulation of the
immunoproteasomal subunits [46]. Though altered prote-
asomal cleavage of endogenous proteins can lead to
an alternative, less immunogenic antigen repertoire, an
adequate mechanism for the association of LMP down-
regulation with an absence of lymph node metastases
remains to be postulated.
Interestingly, we have recently observed that genetic
variation in various APM components is signiﬁcantly
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Although the underlying mechanisms of APM component
loss are largely unknown, the occurrence of single nucle-
otide polymorphisms in the various APM genes could form
a genetic basis predisposing to either mutations, or regu-
latory down-regulation [47, 48].
Partial HLA class I loss was observed to be signiﬁcantly
associated with decreased OS; correspondingly, reports in
colon cancer have shown partial, but not total HLA class I
loss to be associated with worse OS [49]. This ﬁnding can
be explained by the ability of low levels of HLA class I
molecules to provide tumour cells with an escape not only
from cytotoxic T lymphocyte-mediated, but also from
natural killer (NK) cell-mediated cytotoxicity [2]. This
hypothesis is further supported by the association of
decreased survival with total TAP1 loss, which has been
shown previously to lead to partial HLA class I loss
[2, 50–52]. In the present study, an association of loss or
down-regulation of expression of the various APM mole-
cules with aberrant HLA expression was observed. More-
over, the partial HLA loss observed is most likely an
underestimation of the extent of HLA alterations present as
immunohistochemical staining on parafﬁn sections does
not reveal loss of speciﬁc HLA alleles [8]. However, there
are also other aberrations known to lead to HLA class I
alterations and it is plausible to hypothesize that all these
mechanisms can coexist in the same tumour sample.
In conclusion, we have shown here that defective
expression of HLA class I and of various APM components
occurs frequently in cervical carcinoma. Partial HLA class
I loss and total TAP1 loss are associated with decreased
survival, while down-regulation of immunoproteasomal
subunits is associated with decreased risk of lymphogenic
metastasis. Moreover, we report the ﬁrst description of
ERAP1 down-regulation in a human carcinoma, and have
found that this is an independent prognostic parameter for
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123decreased survival. A complete understanding of the
mechanisms and relevance of HLA class I and APM
component down-regulation and immune evasion may
contribute to the rational design of tumour vaccines and
T-cell-based immunotherapies.
Acknowledgements The authors thank Dr. M. Tsujimoto, RIKEN,
Wako, Saitama, Japan for kindly providing the anti-ERAP1 antibody.
References
1. Tindle RW (2002) Immune evasion in human papillomavirus-
associated cervical cancer. Nat Rev Cancer 2:59–65
2. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar J, Lopez-
Botet M, Duggan-Keen M, Stern P (1997) Implications for
immunosurveillance of altered HLA class I phenotypes in human
tumours. Immunol Today 18:89–95
3. Ruiz-Cabello F, Cabrera T, Lopez-Nevot M, Garrido F (2002)
Impaired surface antigen presentation in tumours: implications
for T cell-based immunotherapy. Semin Cancer Biol 12:15–24
4. Seliger B, Maeurer MJ, Ferrone S (2000) Antigen-processing
machinery breakdown and tumour growth. Immunol Today
21:455–464
5. Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I
antigen abnormalities and immune escape by malignant cells.
Semin Cancer Biol 12:3–13
6. Bjorkman PJ, Parham P (1990) Structure, function, and diversity
of class I major histocompatibility complex molecules. Annu Rev
Biochem 59:253–288
7. Natarajan K, Li H, Mariuzza RA, Margulies DH (1999) MHC
class I molecules, structure and function. Rev Immunogenet
1:32–46
8. Koopman LA, van der Slik AR, Giphart MJ, Fleuren GJ (1999)
Human leukocyte antigen class I gene mutations in cervical
cancer. J Natl Cancer Inst 91:1669–1677
9. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glen-
ville S, Telford N, Little AM, Davidson JA, Jimenez P, Ruiz-
Cabello F, Garrido F, Stern P (2000) Multiple mechanisms
underlie HLA dysregulation in cervical cancer. Tissue Antigens
55:401–411
10. Koopman LA, Corver W, van der Slik AR, Giphart MJ, Fleuren
GJ (2000) Multiple genetic alterations cause frequent and heter-
ogeneous human histocompatibility leukocyte antigen class I loss
in cervical cancer. J Exp Med 191:961–976
11. York IA, Rock KL (1996) Antigen processing and presentation
by the class I major histocompatibility complex. Annu Rev
Immunol 14:369–396
12. Gromme M, Neefjes J (2002) Antigen degradation or presentation
by MHC class I molecules via classical and non-classical path-
ways. Mol Immunol 39:181–202
13. Van Kaer L (2002) Major histocompatibility complex class
I-restricted antigen processing and presentation. Tissue Antigens
60:1–9
14. York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg
AL, Rock K (2002) The ER aminopeptidase ERAP1 enhances or
limits antigen presentation by trimming epitopes to 8-9 residues.
Nat Immunol 3:1177–1184
15. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL,
Ferrone S, Seliger B (2005) Defects in the human leukocyte
antigen class I Antigen Processing Machinery in head and neck
squamous cell carcinoma: association with clinical outcome. Clin
Cancer Res 11:2552–2560
16. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M,
Campoli M, Ferrone S (2005) Human leukocyte antigen and
antigen processing machinery component defects in astrocytic
tumours. Clin Cancer Res 11:8304–8311
17. Seliger B, Ritz U, Ferrone S (2006) Molecular mechanisms of
HLA class I antigen abnormalities following viral infection and
transformation. Int J Cancer 118:129–138
18. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B
(2001) Deﬁcient expression of components of the MHC class I
antigen processing machinery in human cervical carcinoma. Int
J Oncol 19:1211–1220
19. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern
PL, Meijer CJ, Walboomers JM (1994) Loss of transporter pro-
tein, encoded by the TAP-1 gene, is highly correlated with loss of
HLA expression in cervical carcinomas. J Exp Med 179:335–340
20. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJ, Walbo-
omers JM, Hunter RD, Dyer PA, Stern PL (1995) Frequency of
down-regulation of individual HLA-A and -B alleles in cervical
carcinomas in relation to TAP-1 expression. Br J Cancer 72:405–
411
21. Cromme FV, van Bommel PF, Walboomers JM, Gallee MP,
Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer CJ
(1994) Differences in MHC and TAP-1 expression in cervical
cancer lymph node metastases as compared with the primary
tumours. Br J Cancer 69:1176–1181
22. Hilders CG, Houbiers JG, Krul EJ, Fleuren GJ (1994) The
expression of histocompatibility-related leukocyte antigens in the
pathway to cervical carcinoma. Am J Clin Pathol 101:5–12
23. Hilders CG, Munoz IM, Nooyen Y, Fleuren GJ (1995) Altered
HLA expression by metastatic cervical carcinoma cells as a factor
in impaired immune surveillance. Gynecol Oncol 57:366–375
24. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ
(1996) Association of allele-speciﬁc HLA expression and histo-
pathologic progression of cervical carcinoma. Gynecol Oncol
62:33–41
25. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR,
Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP,
Sauter G (2001) Tissue microarrays for rapid linking of molecular
changes to clinical endpoints. Am J Pathol 159:2249–2256
Table 4 Histopathological parameters and 5-years survival rates
Overall survival Disease-free survival
% P % P
Depth of inﬁltration
<15 mm (n = 59) 88 90
‡15 mm (n = 51) 60 <0.001 57 <0.001
Vaso-invasion
Absent (n = 68) 81 85
Present (n = 38) 59 0.031 54 0.002
Lymph nodes
Negative (n = 80) 86 86
Positive (n = 27) 43 <0.001 39 <0.001
Histopathological class
SCC (n = 84) 75 76
AC (n = 26) 77 0.924 74 0.662
FIGO stage
£IB1 (n = 52) 82 91
‡IB2 (n = 53) 69 0.060 57 0.002
Cancer Immunol Immunother (2008) 57:197–206 205
12326. Ruiz C, Seibt S, Kuraya KA, Siraj AK, Mirlacher M, Schraml P,
Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Souter G
(2005) Tissue microarrays for comparing molecular features with
proliferation activity in breast cancer. Int J Cancer 118:2190–2194
27. Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies
raised against denatured HLA-B locus heavy chains permit bio-
chemical characterization of certain HLA-C locus products.
J Immunol 137:2299–2306
28. Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies
cross-react with HLA-A and HLA-G: epitope mapping of two
common MHC class I reagents. Mol Immunol 35:177–188
29. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Damm-
acco F (2003) Beta 2-microglobulin-free HLA class I heavy chain
epitope mimicry by monoclonal antibody HC-10-speciﬁc peptide.
J Immunol 171:1918–1926
30. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S,
Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and
characterization of human constitutive proteasome and immu-
noproteasome subunit-speciﬁc monoclonal antibodies. Tissue
Antigens 66:185–194
31. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J,
Hur SY, Kageshita T, Ferrone S (2005) A method to generate
antigen-speciﬁc mAb capable of staining formalin-ﬁxed, parafﬁn-
embedded tissue sections. J Immunol Methods 299:139–151
32. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S
(2003) Endoplasmic reticulum chaperone-speciﬁc monoclonal
antibodies for ﬂow cytometry and immunohistochemical staining.
Tissue Antigens 62:385–393
33. Hattori A, Kitatani K, Matsumoto H, Miyazawa S, Rogi T,
Tsuruoka N, Mizutani S, Natori Y, Tsujimoto M (2000) Char-
acterization of recombinant human adipocyte-derived leucine
aminopeptidase expressed in Chinese hamster ovary cells. J Bio-
chem 128:755–762
34. Saric T, Chang S, Hattori A, York IA, Markant S, Rock KL,
Tsujimoto M, Goldberg AL (2002) An IFN-gamma-induced
aminopeptidase in the ER, ERAP1, trims precursors to MHC
class I-presented peptides. Nat Immunol 3:1169–1176
35. Shibata D, Ando H, Iwase A, Nagasaka T, Hattori A, Tsujimoto
M, Mizutani S (2004) Distribution of adipocyte-derived leucine
aminopeptidase (A-LAP)/ER-aminopeptidase (ERAP)-1 in hu-
man uterine endometrium. J Histochem Cytochem 52:1169–1175
36. Hazelbag S, Gorter A, Kenter GG, van den Broek L, Fleuren GJ
(2002) Transforming growth factor-beta1 induces tumour stroma
and reduces tumour inﬁltrate in cervical cancer. Hum Pathol
33:1193–1199
37. Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans S,
Kennedy S, Kramer MD, Nielsen B, Schmitt M (1998) Quality
control of immunohistochemical evaluation of tumour-associated
plasminogen activators and related components. European BIO-
MED-1 Concerted Action on Clinical Relevance of Proteases in
Tumour Invasion and Metastasis. Eur J Cancer 34:1334–1340
38. Falk K, Rotzschke O (2002) The ﬁnal cut: how ERAP1 trims
MHC ligands to size. Nat Immunol 3:1121–1122
39. Chang SC, Momburg F, Bhutani N, Goldberg AL (2005) The ER
aminopeptidase, ERAP1, trims precursors to lengths of MHC
class I peptides by a ‘‘molecular ruler’’ mechanism. Proc Natl
Acad Sci USA 102:17107–17112
40. Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier
Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert
PM (2005) Concerted peptide trimming by human ERAP1 and
ERAP2 aminopeptidase complexes in the endoplasmic reticulum.
Nat Immunol 6:689–697
41. Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N
(2006) The aminopeptidase ERAAP shapes the peptide repertoire
displayed by major histocompatibility complex class I molecules.
Nat Immunol 7:103–112
42. Yan J, Parekh VV, Mendez-Fernandez Y, Olivares-Villagomez
D, Dragovic S, Hill T, Roopenian DC, Joyce S, Van Kaer L
(2006) In vivo role of ER-associated peptidase activity in tai-
loring peptides for presentation by MHC class Ia and class Ib
molecules. J Exp Med 203:647–659
43. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi
U, Cerundolo V, Man S (2001) Antigen processing defects in
cervical carcinomas limit the presentation of a CTL epitope from
human papillomavirus 16 E6. J Immunol 167:5420–5428
44. Barnden MJ, Purcell AW, Gorman J, McCluskey J (2000)
Tapasin-mediated retention and optimization of peptide ligands
during the assembly of class I molecules. J Immunol 165:322–
330
45. Garbi N, Tan P, Diehl AD, Chambers BJ, Ljunggren H, Momburg
F, Hammerling GJ (2000) Impaired immune responses and
altered peptide repertoire in tapasin-deﬁcient mice. Nat Immunol
1:234–238
46. Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M,
Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC,
Boon T, Gairin JE, Van den Eynde BJ (2000) Processing of some
antigens by the standard proteasome but not by the immuno-
proteasome results in poor presentation by dendritic cells.
Immunity 12:107–117
47. Gostout BS, Poland GA, Calhoun ES, Sohni Y, Giuntoli RL,
McGovern RM, Sloan J, Cha S, Persing DH (2003) TAP1, TAP2,
and HLA-DR2 alleles are predictors of cervical cancer risk.
Gynecol Oncol 88:326–332
48. Cao B, Tian X, Li Y, Jiang P, Ning T, Xing H, Zhao Y, Zhang C,
Shi X, Chen D, Shen Y, Ke Y (2005) LMP7/TAP2 gene poly-
morphisms and HPV infection in esophageal carcinoma patients
from a high incidence area in China. Carcinogenesis 26:1280–
1284
49. Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO,
Scholeﬁeld JH, Durrant LG (2006) Immunosurveillance is active
in colorectal cancer as downregulation but not complete loss of
MHC class I expression correlates with a poor prognosis. Int J
Cancer 118:6–10
50. Seliger B, Maeurer MJ, Ferrone S (1997) TAP off—tumours on.
Immunol Today 18:292–299
51. Young NT, Mulder A, Cerundolo V, Claas FH, Welsh KI (1998)
Expression of HLA class I antigens in transporter associated with
antigen processing (TAP)-deﬁcient mutant cell lines. Tissue
Antigens 52:368–373
52. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S (1999)
Down-regulation of HLA class I antigen-processing molecules in
malignant melanoma: association with disease progression. Am J
Pathol 154:745–754
206 Cancer Immunol Immunother (2008) 57:197–206
123